157 related articles for article (PubMed ID: 11695547)
21. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing.
Venkatachalam S; Tyner SD; Pickering CR; Boley S; Recio L; French JE; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():147-54. PubMed ID: 11695551
[TBL] [Abstract][Full Text] [Related]
22. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
Robinson DE; MacDonald JS
Toxicol Pathol; 2001; 29 Suppl():13-9. PubMed ID: 11695549
[TBL] [Abstract][Full Text] [Related]
23. Diethylstilbestrol (DES): carcinogenic potential in Xpa-/-, Xpa-/- / p53+/-, and wild-type mice during 9 months' dietary exposure.
McAnulty PA; Skydsgaard M
Toxicol Pathol; 2005; 33(5):609-20. PubMed ID: 16178126
[TBL] [Abstract][Full Text] [Related]
24. The syrian hamster embryo (SHE) cell transformation assay: review of the methods and results.
Mauthe RJ; Gibson DP; Bunch RT; Custer L
Toxicol Pathol; 2001; 29 Suppl():138-46. PubMed ID: 11695550
[TBL] [Abstract][Full Text] [Related]
25. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.
French J; Storer RD; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():24-9. PubMed ID: 11695559
[TBL] [Abstract][Full Text] [Related]
26. Panel discussion on the application of alternative models to cancer risk assessment.
Pettit SD
Toxicol Pathol; 2001; 29 Suppl():191-5. PubMed ID: 11695557
[TBL] [Abstract][Full Text] [Related]
27. p53 haploinsufficiency profoundly accelerates the onset of tongue tumors in mice lacking the xeroderma pigmentosum group A gene.
Ide F; Kitada M; Sakashita H; Kusama K; Tanaka K; Ishikawa T
Am J Pathol; 2003 Nov; 163(5):1729-33. PubMed ID: 14578172
[TBL] [Abstract][Full Text] [Related]
28. Delay of DNA-adduct repair and severe toxicity in xeroderma pigmentosum group A gene (XPA) deficient mice treated with 2-amino-1-methyl-6-phenyl-imidazo [4,5-b] pyridine (PhIP).
Imaida K; Ogawa K; Takahashi S; Ito T; Yamaguchi T; Totsuka Y; Wakabayashi K; Tanaka K; Ito N; Shirai T
Cancer Lett; 2000 Mar; 150(1):63-9. PubMed ID: 10755388
[TBL] [Abstract][Full Text] [Related]
29. Benzo[a]pyrene-induced transcriptomic responses in primary hepatocytes and in vivo liver: toxicokinetics is essential for in vivo-in vitro comparisons.
van Kesteren PC; Zwart PE; Schaap MM; Pronk TE; van Herwijnen MH; Kleinjans JC; Bokkers BG; Godschalk RW; Zeilmaker MJ; van Steeg H; Luijten M
Arch Toxicol; 2013 Mar; 87(3):505-15. PubMed ID: 23052197
[TBL] [Abstract][Full Text] [Related]
30. Induction of DNA adducts and mutations in spleen, liver and lung of XPA-deficient/lacZ transgenic mice after oral treatment with benzo[a]pyrene: correlation with tumour development.
de Vries A; Dollé ME; Broekhof JL; Muller JJ; Kroese ED; van Kreijl CF; Capel PJ; Vijg J; van Steeg H
Carcinogenesis; 1997 Dec; 18(12):2327-32. PubMed ID: 9450477
[TBL] [Abstract][Full Text] [Related]
31. Carcinogen-induced inflammation and immunosuppression are enhanced in xeroderma pigmentosum group A model mice associated with hyperproduction of prostaglandin E2.
Miyauchi-Hashimoto H; Kuwamoto K; Urade Y; Tanaka K; Horio T
J Immunol; 2001 May; 166(9):5782-91. PubMed ID: 11313422
[TBL] [Abstract][Full Text] [Related]
32. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
33. Intestinal toxicity and carcinogenic potential of the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in DNA repair deficient XPA-/- mice.
Klein JC; Beems RB; Zwart PE; Hamzink M; Zomer G; van Steeg H; van Kreijl CF
Carcinogenesis; 2001 Apr; 22(4):619-26. PubMed ID: 11285198
[TBL] [Abstract][Full Text] [Related]
34. UV-induced skin carcinogenesis in xeroderma pigmentosum group A (XPA) gene-knockout mice with nucleotide excision repair-deficiency.
Tanaka K; Kamiuchi S; Ren Y; Yonemasu R; Ichikawa M; Murai H; Yoshino M; Takeuchi S; Saijo M; Nakatsu Y; Miyauchi-Hashimoto H; Horio T
Mutat Res; 2001 Jun; 477(1-2):31-40. PubMed ID: 11376684
[TBL] [Abstract][Full Text] [Related]
35. The in vivo rodent test systems for assessment of carcinogenic potential.
van der Laan JW; Spindler P
Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of hormonal carcinogenesis in the p53+/- hemizygous knockout mouse: studies with diethylstilbestrol.
Carmichael PL; Mills JJ; Campbell M; Basu M; Caldwell J
Toxicol Pathol; 2001; 29 Suppl():155-60. PubMed ID: 11695552
[TBL] [Abstract][Full Text] [Related]
37. The Tg.AC (v-Ha-ras) transgenic mouse: nature of the model.
Tennant RW; Stasiewicz S; Eastin WC; Mennear JH; Spalding JW
Toxicol Pathol; 2001; 29 Suppl():51-9. PubMed ID: 11695562
[TBL] [Abstract][Full Text] [Related]
38. Mutagenesis and carcinogenesis in nucleotide excision repair-deficient XPA knock out mice.
van Steeg H; Mullenders LH; Vijg J
Mutat Res; 2000 May; 450(1-2):167-80. PubMed ID: 10838141
[TBL] [Abstract][Full Text] [Related]
39. Mice deficient in the nucleotide excision repair gene XPA have elevated sensitivity to benzo[a]pyrene induction of lung tumors.
Ide F; Iida N; Nakatsuru Y; Oda H; Tanaka K; Ishikawa T
Carcinogenesis; 2000 Jun; 21(6):1263-5. PubMed ID: 10837020
[TBL] [Abstract][Full Text] [Related]
40. The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists.
Floyd E; Mann P; Long G; Ochoa R
Toxicol Pathol; 2002; 30(1):147-56. PubMed ID: 11890468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
